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Abstract
Objective: Major system change (MSC) has multiple, sometimes conflicting, goals and involves implementing change
across a number of organizations. This study sought to develop new understanding of how the role that networks can
play in implementing MSC, using the case of centralization of specialist cancer surgery in London, UK.
Methods: The study was based on a framework drawn from literature on networks and MSC. We analysed 100
documents, conducted 134 h of observations during relevant meetings and 81 interviews with stakeholders involved
in the centralization. We analysed the data using thematic analysis.
Results: MSC in specialist cancer services was a contested process, which required constancy in network leadership
over several years, and its horizontal and vertical distribution across the network. A core central team composed of
network leaders, managers and clinical/manager hybrid roles was tasked with implementing the changes. This team
developed different forms of engagement with provider organizations and other stakeholders. Some actors across the
network, including clinicians and patients, questioned the rationale for the changes, the clinical evidence used to support
the case for change, and the ways in which the changes were implemented.
Conclusions: Our study provides new understanding of MSC by discussing the strategies used by a provider network
to facilitate complex changes in a health care context in the absence of a system-wide authority.
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Background
Major system change (MSC) is defined as a ‘coordinat-
ed, system-wide change affecting multiple organizations
and care providers, with the goal of making significant
improvements in efficiency of health care delivery, the
quality of patient care, and population-level patient out-
comes’.1 Of growing importance and relevance interna-
tionally, examples of MSC include the centralization of
specialist services to reduce variations in access, increase
patient volumes and improve patient outcomes, as evi-
denced in cancer care.
There is increasing understanding of the impact of
centralization in different areas of health care deliv-
ery,2–5 but there remain considerable gaps in knowl-
edge about how MSC is planned and implemented.
There may also be negative consequences of MSC as
clinical teams, therapeutic relationships and collective
identities may be disrupted, possibly without generat-
ing promised health care benefits for the population.6
In this article, we seek to develop new understanding
of MSC implementation by analysing the centralization
of specialist cancer surgery in London, UK. This change
was developed and implemented by a network of
National Health Service (NHS) provider organizations
and involved centralization of services across four
cancer pathways (bladder, prostate, renal, and
oesophago-gastric cancers). Our main focus is the role
of the provider-led network in managing the MSC. The
case presents a departure from experiences of MSC in
other areas of health care delivery in the UK, where
regional system-wide organizations were previously
identified as playing a central role in the implementation
of MSC.2
We analyse the mechanisms and strategies used by
network leaders and managers to implement MSC and
develop new understanding of how these can influence
its successful implementation. Defined as ‘formal and
informal communication between diverse, but related,
organizations to manage the flow of public services
across the whole area of service provision’,7 networks
can be used to work across institutional and profes-
sional boundaries, promoting joint working arrange-
ments and the flow of knowledge, potentially
improving patients’ access to and quality of care.8
Networks can also be inherently hierarchical, with
some organizations in the network playing a more
‘dominant’ role in decision-making processes.9,10
They have the potential to address ‘wicked problems’,
that is, problems requiring systemic response, behav-
iour change, and engagement across organizations.11
Our study explored the strategies used by a network
of provider organizations to implement centralized spe-
cialist cancer surgery, considering network effective-
ness in relation to the network’s ability to achieve
this.8 We studied stakeholder preferences for centraliz-
ing services, the impact of the changes in relation to
clinical, cost-effectiveness, patient experience and pro-
cess outcomes.8,12
Centralizing specialist cancer surgery in London
The centralization of specialist cancer surgery followed
the publication by the NHS Commissioning Support
for London of the 2010 Case for Change and Model
of Care for Cancer Services, which recommended the
establishment of clinically led provider networks to
optimize the whole pathway of cancer care and
reduce variation.13,14 In 2012, a network of 12 provider
organizations was commissioned to oversee the provi-
sion of cancer services for north east and north central
London and west Essex (covering a population of 3.2
million). The aim was to improve cancer patients’ expe-
rience of care, increase access to a wider range of treat-
ment options and participation in clinical trials, and,
ultimately, to improve outcomes.15 One of the main
changes planned by the network was the centralization
of specialist surgical services.
Pre-centralization, the number of centres providing
specialist cancer surgery in London varied by pathway
(for instance, nine in renal cancer and three in
oesophago-gastric cancer) (Figure 1). Patients sus-
pected of having cancer were referred to their local
cancer centre for diagnostic testing; those diagnosed
with cancer received treatment either at the same
local cancer centre or were referred to a specialist
centre. However, referral processes and the care
received by patients varied across centres, with for
example, robotic surgery for prostate and bladder
cancer only available in certain specialist cancer sur-
gery units. Surgery for renal cancer was performed in
specialist and local non-specialist centres, potentially
limiting the surgical options afforded to patients;
also, patients were not guaranteed to see a specialist
out of hours or at weekends. There was substantial
variation in patient volumes across specialist centres
and in the number of cases per surgeon.
The MSC involved reducing the number of centres
delivering specialist cancer surgery from four to one for
the prostate and bladder pathway, from nine to one for
the renal pathway and from three to two for the
oesophago-gastric pathway. Pathway boards led by
clinical experts in the tumour type were established to
oversee the service specifications of specialist and local
centres and the implementation of the changes, and to
monitor/improve care delivery. Pathway changes also
introduced specialist multi-disciplinary teams (SMDTs)
to facilitate clinical input from a wide range of profes-
sional groups across the network and to meet regularly
with local multi-disciplinary teams (MDTs) based at
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local centres to discuss patient cases. These meetings
facilitated the coordination of patient care and sharing
of expertise across the network of providers. All
planned changes were fully implemented by April 2016.
Methods
Data collection and sampling
We conducted a qualitative study using document
review, non-participant observation and in-depth inter-
views from September 2015 to April 2019. The study
focused on 10 sites in London, sampled as: (1) specialist
centres, (2) sites that used to deliver specialist surgery
but lost these services as a result of the centralization,
and (3) sites that were local centres and remained local
after the reconfiguration. Documentary evidence (100
documents) was gathered from online resources and
from people involved in the planning and implementa-
tion of the centralization. We conducted non-participant
observation (134h) of relevant board meetings, SMDT
meetings at specialist and local centres, and other events
associated with the centralization. A sampling frame-
work of potential participants to approach for inter-
views as well as relevant meetings to observe was
developed in collaboration with staff who played a key
role in the planning and implementation of the central-
ization. Observations were recorded in the form of
unstructured field notes and through a structured obser-
vation guide. We interviewed stakeholders (n¼ 81)
involved in the centralization of cancer surgery across
London, identified through a review of documentary
evidence on the changes and snowball sampling; partic-
ipants were selected present a range of views on the
MCS (Table 1). Only one participant refused to take
part in the study.
Potential interview participants were contacted by
email or telephone and provided with a participant infor-
mation sheet. Interviews were conducted in person or via
telephone using an interview topic guide which covered
the different stages of the centralization. The topic guide
was designed in collaboration with staff who had played
a key role in the planning and implementation of the
centralization. Interviews lasted approximately 50min
and were audio recorded then professionally transcribed.
Written informed consent was obtained at the beginning
of each interview. Permission to observe meetings was
obtained from the Chair in advance. Participants were
given the option to opt out of observations. No members
of staff opted out of the observations.
Data analysis
Interview transcripts, observation notes and documen-
tary evidence were analysed using thematic analysis.16
Data from the interviews shed light on perceptions
and experiences of the re-organization. The observations
pointed to the ways in which the implementation was
carried out in practice. The documentary analysis
allowed us to capture retrospectively the early stages
of centralization design and planning as well as the ‘offi-
cial’ documents guiding implementation. We conducted
an initial familiarization stage and identified preliminary
codes. We then examined these codes in relation to our
framework. Codes were grouped into themes concerning
the main features guiding the planning and implemen-
tation of the centralization. We re-examined our frame-
work based on these themes. Emerging findings were
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Figure 1. Illustrates pre and post centralization models of care that were implemented.
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shared with a wide stakeholder group. Feedback was
used to refine the focus of the analysis.
Ethical approval
The mixed-methods evaluation received ethical approv-
al in July 2015 from the Proportionate Review Sub-
committee of the NRES Committee Yorkshire & the
Humber – Leeds (Reference 15/YH/0359).
Results
Our analysis of the stages involved in the design and
implementation of the centralization pointed to a
series of factors that contributed to the successful
implementation of the re-organization. We describe
these factors below.
Central network leadership drove the changes
forward
As mentioned earlier, a network of provider organizations
was commissioned to oversee the implementation of the
centralization of specialist cancer surgery. A key facilitator
of the implementation was the Chief Medical Officer
(CMO) who was based at a local academic health science
partnership (these partnerships bring together academic
institutions, health care organizations, local authorities,
industry and members from the third sector). Although
a clinician by background, the CMO’s clinical specialty
was not part of the centralization. The CMO was also
based at an ‘independent’ organization, in the sense that
it was not a part of the any of the provider organizations
in the network. The CMO worked closely with a network
board (an independent skills-based board formed of
experts external to London and chaired by a former
cancer patient). This Board was created to oversee a bid-
ding process where provider organizations would be
selected to host specialist centres. Where consensus was
not achieved and competing bids were submitted by pro-
vider organizations, the proposals were reviewed external-
ly by clinical experts selected by the Board. The Board
then developed recommendations on the sites that should
take on the role of specialist centres for each pathway.
These were agreed by the chief executives and medical
directors of the network provider organizations.
Our data showed that the CMO and chair of the
Board were perceived by many managers and clinicians
across the network as providing strong, objective leader-
ship, with a clear vision and mandate to implement the
changes outlined in the Model of Care. Some network
members suggested that the relative independence of the
CMO role and of some members of the Board allowed
the central leadership of the network (that is, the CMO
and the Board Chair) to be seen as ‘neutral’. However, as
will be explained later, other actors in the network asso-
ciated central leadership figures with dominant provider
organizations, that is, those organizations that obtained
most of the specialist cancer workload as a result of the
reconfiguration. Constancy in network leadership
(mainly the CMO and the Board Chair) over time was
also perceived to have enabled the implementation of
changes, even in light of the profound organizational
restructuring of the health care system during and after
the 2012 health and social care reform that took place in
England as a whole at that time.
The central leadership team drew from existing evi-
dence on the potential benefits of centralizing specialist
cancer surgery and previous experiences of centraliza-
tion as a way to justify the changes:
At the initial stages it was very much based on the
evidence that we were putting together, we were driving
it based on what you would probably drive most
changes on, which is pure data. (LON 15, network
manager)
Data were not always readily available, and some inter-
view participants reported to have spent a considerable
amount of time searching for and collating data and
developing new sources when these were not available.
There were some discussions about the quality, verac-
ity, and inclusivity of the data used to guide decisions
on the reconfiguration. Some local surgeons expressed
concerns about how the data were used:
Table 1. Profile of interview participants.
Participant group Number
Network managers and other network staff
members
8
Local contexta 9
Patient representatives 3
Urology Pathway Boardb members 4
Oesophago-gastric (OG) Pathway Boardb
members
4
OG cliniciansc from provider organizations
(specialist and local centres)
14
Urology cliniciansc from provider organizations
(specialist and local centres)
30
OG managers from provider organizations
(specialist and local centres)
2
Urology managers from provider organizations
(specialist and local centres)
7
aCommissioners (involved in the planning and purchasing of NHS and
publicly funded social care services), academics, members from organi-
zations outside of the network.
bPathway boards are led by clinical pathway directors and include rep-
resentation from patients, primary care and cancer professionals from
across the London area.
cSurgeons, nurses, oncologists, allied health professionals, pathologists
and radiologists.
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So we were easily the highest volume, best audited
results, best research in the sector; that’s why we were
particularly upset when renal cancer was given to [the
specialist centre] who had no history of really renal
cancer work at all. (LON 47, urology surgeon)
We were suddenly turning around to surgeons who had
been operating 10, 15, 20 years of their career, doing
the same procedure perhaps 50 to 100 times a year, and
asking them to centralise their cases to [the specialist
centre], who at the time, were only doing about 20 or
30 cases a year. So, there was the perception that it was
very politically driven rather than an objective criteria-
driven process. (LON 26, urology surgeon)
Network managers supported leaders
The CMO and Chair of the Board were central to the
leadership, but staff members in managerial and clini-
cal roles across other levels of the network also played
an important role:
So, keeping the Chief Exec on board, keeping the
Medical Directors on board, keeping the clinicians
themselves on board and brought out, so all of those
levels, so really try to make sure that the staff at ground
level, knew that there was a place in this and that this
was collective, working towards a shared ambition.
(LON38, commissioning support staff member)
The network managers played an instrumental role in
supporting leaders, mediating relationships across sites,
and facilitating the day-to-day requirements of the
changes. The Board appointed clinical leads to chair
pathway boards and design the integrated cancer care
pathways15:
So basically, we, being the [network] Board, prompted,
encouraged, supported the pathway boards, which
were almost entirely clinical, so that in a sense we
gave them some degree of institutional coverage and
support, external challenge through our Board mem-
bers and a process under which they brought recom-
mendations forward in a structured and disciplined
way that addressed all the various things that needed
to be addressed. (LON4, network board member)
The network core team designated, arranged training
for, and supported leaders for each of the pathway
boards; these leaders became a core leadership team
that remained beyond the implementation of the
changes. Leaders were selected for their skills in leading
teams, engaging with a wide range of stakeholders, and
building relationships, and changing culture. Leaders
needed to act in hybrid roles, that is, combining clinical
knowledge and managerial skills. An early planning
document stated, ‘as we interview pathway directors,
we will carefully screen for those with the leadership
competencies to spread our culture quickly through the
community’.17 The screening process was based on the
use of competency models and role play simulations.17
The appointed leaders took part in personal leadership
development sessions.
Engagement across provider organizations
The network encouraged the pathway leads to engage
with a wide range of stakeholders within the network
and ‘develop relationships with colleagues across the
care pathway’.17 These relationships were considered
central aspects of the objectives of the pathway leads
and the leadership development programme mentioned
above. Leaders used their own styles to create change.
The successful implementation of the changes was
associated with leaders who were viewed as trusted,
had a clear vision, showed dedication and perceived
as good at building relationships:
So, he was a tremendous leader [. . .]. He was great at
bringing people together, he was so unfazed and he
wasn’t, he had no ego, he wasn’t brisk or brash or
bold in what he was trying to do, he just worked quietly
with everybody, he talked to them and said I want you
involved. If you are not involved, you are choosing not
to be. (LON 9, network manager)
Planning the changes entailed the inclusion of represen-
tatives from all provider organizations. There was an
expectation that if all organizations were involved
during early stages the implementation of the changes
would be smoother as all organizations would have a
sense of ownership of the new pathways, building
momentum to drive the changes forward and sustain
the changes over time.
However, engagement took place in a context inter-
preted by some as infused with competition for future
surgical activity:
[T]here was a lot of concern from staff over the effect
on their service’s future and sustainability and on a
personal level, I think a lot of staff were concerned
about their own personal practice and professional
future. (LON 40, specialist centre staff member)
There was also a concern that specialist centres would
be ‘taking over’ the network and absorbing all of the
specialist care, leaving local centres without the
ability to retain surgical expertise and recruit new mem-
bers of staff.
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Engagement of other stakeholders
Commissioners had a legal obligation to lead a public
engagement process on the centralization.18 Following
the 2012 reforms to the NHS in England, centraliza-
tions had to be authorized or approved by Clinical
Commissioning Groups (newly formed payer organiza-
tions); the network Board could only make recommen-
dations to commissioners. Whilst commissioners were
kept informed in the early stages of planning, they only
became more involved in 2013, when commissioning
structures consolidated. Commissioners were involved
in developing the reporting and governance mecha-
nisms for the implementation of the changes (in the
form of Gateway Reviews, a process by which pro-
grammes and projects are examined at key decision
points in their lifecycle), and were also involved in car-
rying out two phases of an engagement process (late
2013 and in 2014), which comprised meetings with
health care professionals, drop-in sessions for members
of the public, and workshops.
I think when the new commissioning structures came in
there was probably legal advice, strong legal advice to
say, “If you want to have a really robust process, you
need to be, have the commissioners working with this
[. . .].” The commissioners had a duty to look at those
options with an open mind and review them and
then make their own recommendations in an options
appraisal. (LON36, Commissioning support staff
member)
The engagement aimed to bring together a wide range
of stakeholders to ‘gain their views and experience of
current services and hear their aspirations for the
health services they would receive in the future’.18
This engagement process included considering recom-
mendations made by the Board as well as additional
options not recommended by this Board (i.e. indepen-
dent assessments). Patients, families and members of
the public were asked about these changes through
public meetings.
Some patient groups used this engagement process
to express their concerns about the centralization plans.
They felt the needs of patients would not be considered
a priority in a centralized model of care; for example,
some patients would be forced to travel for longer peri-
ods of time to undergo specialist surgery:
When you did raise any objections or problems, you
felt you were being fobbed off, as I say, the reduced
[travel] fares was the hilarious one, yeah, and it was
more just, they were having discussions about getting
extra parking spaces. We knew that from our other
contacts with other groups and so on that East
London and/or the eastern boroughs we call them,
there was quite a resistance about going up west.
(LON13, patient representative)
Patient representatives who had worked with members
of the network and were in favour of the changes
responded to these patients’ opposition by publicly
highlighting the potentially positive effects of the
changes on patient care, experience and health out-
comes. Travel was recognized as a burden, but not a
barrier to care: ‘my personal view is I think if you have
got the best standards of treatment people will travel’
(LON10, patient representative).
Discussion
Our analysis of implementing the centralization of
cancer surgical services across a network of providers
in London combined existing knowledge about pro-
cesses that facilitate MSC and the characteristics and
strategies used by network leaders and managers to
agree and create change. These changes were imple-
mented after the major 2012 health care reform in
England, in a context with substantially reduced
system-wide, or ‘top-down’, authority. Our findings
point to the role played by central network leadership
figures and network managers in creating, supporting,
and maintaining consensus in order to drive the
changes. The network relied on key leadership figures
as well as distributed, or more horizontal, forms of
leadership across the network to bring together a
diverse group of stakeholders and drive change. As in
other types of health care networks, an emphasis on the
‘political neutrality’ of central network leaders and the
Board was employed as a strategy to position them-
selves outside of the competitive health care landscape
and drive the changes forward.9
Constancy in the people who enacted leadership
roles allowed the network to drive the changes forward,
even in the face of the organizational restructuring of
the health care system. Senior clinical leaders who
acted as pathway leads occupied hybrid leadership
roles,19 where they assumed management responsibili-
ties whilst retaining their clinical role. This granted
them credibility within the network due to their clinical
knowledge19 (also referred to as ‘reputational fram-
ing’)9 and allowed them to use their managerial skills
to bridge organizational boundaries and bring together
representatives from multiple professional groups.8
Clinical leadership of the changes was prioritized
and actively fostered, as clinicians were strategically
recruited and trained as leaders, developing their
hybrid roles. Leadership training was based on inclu-
sive models of participation in the changes and gave
clinicians the skills to create ‘buy-in’ across sites and
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bring stakeholders on board. The work of these clinical
leaders depended heavily on the support provided by
programme-level network managers, who acted as
facilitators, connections or bridges across organiza-
tions and professional groups.
Early engagement of a wide range of stakeholders
led to the creation of local champions across different
layers and sectors of the networks, building up the
pressure to drive change. Fitzgerald et al. have dis-
cussed the role played by this cumulative effect of dis-
tributed leadership on organizational change and
service improvement, where leadership enacted across
multiple tiers creates a driving force to move events in a
particular direction and sustain these changes through
time.20 The changes were fully implemented, but many
clinicians and managers continued to express disagree-
ment with the rationale for the centralization, the evi-
dence used to justify the changes and the ways in which
the changes were made (i.e. how sites were selected to
act as specialist centres), even several years after
implementation.
Consistent with other studies of MSC,3,21 we found
that patient and public involvement served various pur-
poses, from a genuine interest in ensuring that the
needs and interests of patients were represented in the
planning and implementation of the changes, to more
instrumental forms of involvement (i.e. to minimize
resistance or act as champions). Engagement of com-
missioners was difficult in early stages, because of the
wider system reform that involved a reorganization of
commissioning landscape in England, as noted earlier.
Limitations
The retrospective nature of some of the interviews
meant they could have been influenced by recall bias.
To reduce the risk of bias, we used documentary evi-
dence to complement interviewees’ narration of past
events. We made an effort to maintain an inclusive
sampling strategy, but we might have overlooked rele-
vant individuals. Our study analysed the implementa-
tion of MSC in a specific health care area and in a
predominantly urban setting; additional work is
required to explore the role of provider networks in
MSC in other specialties and contexts.
Conclusions
Our study of the role of the network in the centraliza-
tion of specialist cancer surgery has shed light on the
strategies that may be used by networks of provider
organizations to implement MSC in health care con-
texts in the absence of a system-wide authority. Our
study extends previous frameworks developed for the
study of MSC, which pointed to the need for a
combination of top-down and bottom-up leadership
to implement MSC1,12 by describing the role networks
can play in facilitating MSC, and the processes of nego-
tiation involved in the implementation of such changes.
In the case of our study, MSC in specialist cancer
was a contested process, where actors across the net-
work, including clinicians and patients, questioned the
rationale for the changes, the clinical evidence behind
it, and the ways in which the changes were made.
A core central team composed of network leaders,
managers and clinical/manager hybrid roles was able
to drive the changes forward by developing different
forms of engagement with provider organizations, dis-
tributing leadership across vertical and horizontal
layers, and maintaining constancy in central leadership
over time.
As health care systems across the world turn to net-
works as a potentially valuable organizational model
for health care delivery,22 greater attention needs to be
paid to the role of these networks in transforming care,
and which factors influence/facilitate their contribu-
tion. Future research should focus on the impact
of such organizational forms on patient and
population outcomes and the identification of network
leadership styles that might be more successful in deliv-
ering MSC.
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